钙化对甲状腺肿瘤良恶性判断的意义及其分子生物学机制

龚婷; 王家东

doi:10.13201/j.issn.1001-1781.2012.16.010

钙化对甲状腺肿瘤良恶性判断的意义及其分子生物学机制

龚婷,
王家东^,

- 1 上海交通大学医学院附属仁济医院耳鼻咽喉-头颈外科(上海, 200127)

详细信息

通讯作者: 王家东,E-mail:drjiadongw@yahoo.com.cn

中图分类号: R736.1

收稿日期: 2011-09-28

The analysis of the calcification in differentiating malignant thyroid neoplasm and the molecular mechanisms for the formation of the calcification

GONG Ting,
WANG Jiadong^,

More Information

Corresponding author: WANG Jiadong, E-mail: drjiadongw@yahoo.com.cn

Received Date: 28 September 2011

摘要

- 钙化 /
- 甲状腺肿瘤 /
- 沙粒体 /
- Runx2 /
- 骨钙蛋白 /
- 骨桥蛋白 /
- CD44v6
Abstract: The purpose of this review is to investigate the value of the calcification in differentiating malignant thyroid neoplasm and the molecular mechanisms for the formation of the calcification.Many published reports have proved the presence of calcifications in thyroid neoplasm and calcified nodules in these studies are more frequently malignant than noncalcified nodules.Through viewing the related references,we found that psammoma bodies(PBs),Runx2,osteocalcin,osteopontin,CD44v6 play an important role in the molecular mechanisms in the formation of the calcification in PTC.But further study is required for elucidating the mode of action.
- calcification /
- thyroid neoplasm /
- psammoma bodies /
- Runx2 /
- osteocalcin /
- osteopontin /
- CD44v6

HTML全文

参考文献(28)

[1]	KHOO M L, ASA S L, WITTERICK I J, et al. Thyroid calcification and its association with thyroid carcinoma[J]. Head Neck, 2002, 24: 651-655.
[2]	LU Z, MU Y, ZHU H, et al. Clinical value of using ultrasound to assess calcification patterns in thyroid nodules[J]. World J Surg, 2011, 35:122-127.
[3]	TRIGGIANI V, GUASTAMACCHIA E, LICCHELLI B, et al. Microcalcifications and psammoma bodies in thyroid tumors[J]. Thyroid, 2008, 18:1017-1018.
[4]	WANG N, XU Y, GE C, et al. Association of sonographically detected calcification with thyroid carcinoma[J]. Head Neck, 2006, 28:1077-1083.
[5]	CHEN G, ZHU X Q, ZOU X, et al. Retrospective analysis of thyroid nodules by clinical and pathological characteristics, and ultrasonographically detected calcification correlated to thyroid carcinoma in South China[J]. Eur Surg Res, 2009, 42: 137-142.
[6]	ENDO T, OHTA K, KOBAYASHI T. Expression and function of Cbfa-1/Runx2 in thyroid papillary carcinoma cells[J]. J Clin Endocrinol Metab, 2008, 93:2409-2412.
[7]	MOON W J, JUNG S L, LEE J H, et al. Benign and malignant thyroid nodules: US differentiation—multicenter retrospective study[J]. Radiology, 2008, 247: 762-770.
[8]	SALMASLIOGLU A, ERBIL Y, DURAL C, et al. Predictive value of sonographic features in preoperative evaluation of malignant thyroid nodules in a multinodular goiter[J]. World J Surg, 2008, 32:1948-1954.
[9]	BAI Y, ZHOU G, NAKAMURA M, et al. Survival impact of psammoma body, stromal calcification, and bone formation in papillary thyroid carcinoma[J]. Mod Pathol, 2009, 22:887-894.
[10]	PUNTHAKEE X, PALME C E, FRANKLIN J H, et al. Fine-needle aspiration biopsy findings suspicious for papillary thyroid carcinoma: a review of cytopathological criteria[J]. Laryngoscope, 2005, 115: 433-436.
[11]	DAS D K. Psammoma body: a product of dystrophic calcification or of a biologically active process that aims at limiting the growth and spread of tumor[J]? Diagn Cytopathol, 2009, 37:534-541.
[12]	TSUCHIDA T, MATSUMOTO M, SHIRAYAMA Y, et al. Observation of psammoma bodies in cultured meningiomas: analysis of three-dimensional structure using scanning and transmission electron microscopy[J]. Ultrastruct Pathol, 1996, 20: 241-247.
[13]	SUGHRUE M E, KANE A J, SHANGARI G, et al. Prevalence of previous extracranial malignancies in a series of 1228 patients presenting with meningioma[J]. J Neurosurg, 2010, 113:1115-1121.
[14]	DAS D K, MALLIK M K, HAJI B E, et al. Psammoma body and its precursors in papillary thyroid carcinoma: a study by fine-needle aspiration cytology[J]. Diagn Cytopathol, 2004, 31: 380-386.
[15]	CAMERON R I, MCCLUGGAGE W G. Extensive psammomatous calcification of the uterus and cervix associated with a uterine serous carcinoma[J]. J Clin Pathol, 2004, 57: 888-890.
[16]	JOHANNESSEN J V, SOBRINHO-SIMOES M. The origin and significance of thyroid psammoma bodies[J]. Lab Invest, 1980, 43: 287-296.
[17]	DAS D K, SHEIKH Z A, GEORGE S S, et al. Papillary thyroid carcinoma: evidence for intracytoplasmic formation of precursor substance for calcification and its release from well-preserved neoplastic cells[J]. Diagn Cytopathol, 2008, 36: 809-812.
[18]	TUNIO G M, HIROTA S, NOMURA S, et al. Possible relation of osteopontin to development of psammoma bodies in human papillary thyroid cancer[J]. Arch Pathol Lab Med, 1998, 122: 1087-1090.
[19]	MARTIN J W, ZIELENSKA M, STEIN G S, et al. The role of RUNX2 in osteosarcoma oncogenesis[J]. Sarcoma, 2011, 2011:282745.
[20]	YAMAGUCHI A, KOMORI T, SUDA T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1[J]. Endocr Rev, 2000, 21:393-411.
[21]	TYSON K L, REYNOLDS J L, MCNAIR R, et al. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification[J]. Arterioscler Thromb Vasc Biol, 2003, 23:489-494.
[22]	JUNG C, OU Y C, YEUNG F, et al. Osteocalcin is incompletely spliced in non-osseous tissues[J]. Gene, 2001, 271:143-150.
[23]	GOUVEIA C H, SCHULTZ J J, BIANCO A C, et al. Thyroid hormone stimulation of osteocalcin gene expression in ROS 17/2. 8 cells is mediated by transcriptional and post-transcriptional mechanisms[J]. J Endocrinol, 2001, 170: 667-675.
[24]	COPPOLA D, SZABO M, BOULWARE D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies[J]. Clin Cancer Res, 2004, 10(1 Pt 1):184-190.
[25]	BRIESE J, CHENG S, EZZAT S, et al. Osteopontin(OPN) expression in thyroid carcinoma[J]. Anticancer Res, 2010, 30:1681-1688.
[26]	MAKI M, HIROTA S, KANEKO Y, et al. Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma: a possible association with calcification of psammoma bodies[J]. Pathol Int, 2000, 50: 531-535.
[27]	WAI P Y, KUO P C. The role of Osteopontin in tumor metastasis[J]. J Surg Res, 2004, 121:228-241.
[28]	GUARINO V, FAVIANA P, SALVATORE G, et al. Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness[J]. J Clin Endocrinol Metab, 2005, 90:5270-5278.